Please login to the form below

Not currently logged in


This page shows the latest carfilzomib news and features for those working in and with pharma, biotech and healthcare.

Amgen set for Kyprolis label boost after CHMP backing

Amgen set for Kyprolis label boost after CHMP backing

The Committee for Medicinal Products for Human Use (CHMP) has given the go-ahead for Amgen to add survival data to the labelling for its multiple myeloma treatment Kyprolis (carfilzomib).

Latest news

More from news
Approximately 5 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2013 Pharma deals during August 2013

    Indeed it is the fifth-largest biotechnology deal ever. The crown jewel Kyprolis (carfilzomib) is a proteasome inhibitor for the treatment of multiple myeloma which was launched in 2012 and has ... In 2012 these drugs generated $289.6m in revenue for Onyx

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...